Company Overview: HALO

Upcoming Projects (HALO)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (HALO)

Discussing Antares's and Lipocine's TLANDO for testosterone replacement therapy, following its receipt of US FDA approval March 29, 2022
Tickers: ATRS, LPCN, HALO
Executed On: Apr 13, 2022 at 04:00 PM EDT

Expired Projects (HALO)

Understanding how Halozyme’s Enhanze fits in the drug delivery market space, and its prospect for the future
Tickers: HALO, ROG.VX
Execute By: Jul 02, 2018

Upcoming & Overdue Catalysts (HALO)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (HALO)

Halozyme (HALO) announces termination of its development for PEGPH20
Ticker: HALO
Occurred on: Nov 04, 2019
Halozyme Therapeutics (HALO) to begin Phase 1b open label study—under MORPHEUS platform—on combination Tecentriq and PEG PH20 treating metastatic biliary of gallbladder cancer in second half of 2017
Ticker: HALO
Occurred on: Aug 08, 2017
In the second half of 2017, Halozyme Therapeutics (HALO) preparing to commence Phase 1 trial on combination of PEG PH20 and atezolizumab in treating gallbladder tumors
Ticker: HALO
Occurred on: Jul 13, 2017
Halozyme Therapeutics (HALO) to commence Phase 1b/2 open label trial—under MORPHEUS platform—on PEG PH20, testing six tumors, including gastrointestinal, in 2017
Ticker: HALO
Occurred on: Jul 13, 2017
Following preclinical trial, Halozyme Therapeutics (HALO) preparing to commence Phase 1 trial—testing combination of PEG PH20 and atezolizumab in treating pancreatic, gastric tumors among others—In the second half of 2017
Ticker: HALO
Occurred on: Jul 13, 2017
Having used Halozyme Therapuetics' ENHANZE technology ,Roche’s is awaiting June FDA action date on rituximab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma
Tickers: RHHBY, HALO
Occurred on: Jun 23, 2017
Halozyme Therapeutics (HALO) to release HALO-202 study data on combination of PEG PH20 and gemcitabime in treating pancreatic cancer in 2017
Ticker: HALO
Occurred on: Jan 05, 2017
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Rituximab
Tickers: HALO, RHHBY
Occurred on: Nov 03, 2016
PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients
Ticker: HALO
Occurred on: Oct 04, 2016
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
Ticker: HALO
Occurred on: Jul 25, 2016
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
Ticker: HALO
Occurred on: Jun 04, 2016
Phase 2 PFS data of PEGPH20 for pancreatic cancer due Q4 2016
Ticker: HALO
Occurred on: Jun 04, 2016
Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE And Gemcitabine
Ticker: HALO
Occurred on: Mar 16, 2016
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly to develop drugs based on ENHANZE
Tickers: HALO, LLY
Occurred on: Dec 21, 2015

Strategic Initiatives (HALO)

Roche (RHHBY) and Halozyme (HALO) Sign Collaboration Agreement to Evaluate PEGPH20 and Tecentriq in Eight Types of Tumors
Tickers: HALO, RHHBY
Announcement Date: Nov 10, 2016
Halozyme enteres into a $150M credit agreement with Roche and Baxalta secured by future royalties of ENHANZE under its collaborations with the two firms; The debt transaction closed in January 2016
Ticker: HALO
Announcement Date: Jan 26, 2016

HALO Overview